Company intelligence / Profile preview

Bergamo

Taboão da Serra, São Paulo, Brazilbergamobrasil.com.br ↗

Ownership: Private
Employees: ~190
Development stage: Other

Overview

Bergamo is a leading manufacturer of oncological injectables and other hospital-use pharmaceuticals in Brazil. The company has a portfolio of at least 19 commercialized products with significant expertise in oncology and biologics. It was acquired by Amgen in 2011 to strengthen Amgen’s presence in Latin America. In October 2022, Blau Pharmaceuticals signed an agreement to acquire the company from Amgen for $28 million.

Therapeutic areas: HematologyOncologyOther
Modalities: Small moleculeBiologic
Industry: Biotech

Drug pipeline

1 asset

Actiparin

Approved

Partnerships

Mantercorp (historical, for Amgen distribution)

Beyond the preview

Go deeper on Bergamo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bergamo.

Explore the full profile